Merck KGaA Raises 2026 Profit Guidance for Third Time

How much did Merck KGaA raise its 2026 guidance?

The adjusted EBITDA range increased from €5.9 billion–€6.3 billion to €6.2 billion–€6.4 billion, while the net-sales forecast rose from €21.0 billion–€21.8 billion to €21.5 billion–€21.9 billion.

Orbitrum Investor Impact

Why does the upgrade matter for Merck KGaA's investment case?

The higher forecast reflects stronger underlying performance, foreign-exchange effects and the planned Bio-Techne acquisition. Merck now expects 2026 organic EBITDA pre growth of 3%–5%, with an additional portfolio contribution from Bio-Techne and an expected foreign-exchange impact of -2% to 0%.

Does Merck's third-quarter performance support the higher profit forecast?

Third-quarter net sales increased 5.8% year on year to €5.63 billion, including 5.1% organic growth, but EBITDA pre increased just 0.8% to €1.68 billion, with organic growth of 0.4%. The EBITDA pre margin declined from 31.4% to 29.9%, as strong Life Science and Electronics performance was offset by prior-year one-off effects.

Could the guidance increase support Merck KGaA shares?

The higher adjusted earnings outlook can strengthen the investment case for Merck KGaA's publicly traded shares on Xetra and Frankfurt, but modest third-quarter organic EBITDA growth and dependence on the expected Bio-Techne contribution remain important qualifications.

What should investors watch next?

The main near-term milestone is the Bio-Techne acquisition closing, which Merck described as on track and expected soon. Its Life Science forecast assumes the acquisition contributes from December 2026, although the company cautioned that the actual closing date may differ.